Clinical Trial Update: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

View source ↗

Summary

Expanded Access Protocol update for idecabtagene vicleucel in multiple myeloma patients that are nonconforming for commercial release; provides current status o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Idecabtagene vicleucel (idecabtagene vicleucel)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Status: AVAILABLE